Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Particle therapy for T3N0M0 non-small cell lung cancer: a Japanese nationwide prospective registry study.

Created on 13 Nov 2026

Authors

Masaki Nakamura, Nobuteru Kubo, Kazushi Maruo, Masao Murakami, Hiromitsu Iwata, Sunao Tokumaru, Takahiro Waki, Genki Adachi, Kimihiro Shimizu, Yasushi Goto, Takayuki Hashimoto, Hitoshi Ishikawa, Hiroaki Suefuji, Hideyuki Harada, Yoshiyuki Shioyama

Published in

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. Pages 111865. Nov 12, 2026. Epub Nov 12, 2026.

Abstract

Particle therapy offers dosimetric advantages over conventional photon therapy, potentially minimizing toxicities for larger tumors. This study evaluated the clinical outcomes and safety of particle therapy for cT3N0M0 non-small cell lung cancer (NSCLC) using a Japanese nationwide prospective registry.
This multicenter prospective observational registry study included patients with cT3N0M0 NSCLC who were treated with proton beam therapy or carbon-ion radiotherapy between May 2016 and June 2021. Overall survival (OS), progression-free survival (PFS), cumulative incidence of local failure (LF), and adverse events were evaluated. Prognostic factors were compared using the Cox proportional hazards model and the cumulative incidence curves were compared using the Fine-Gray model.
A total of 96 patients were evaluated. With a median follow-up of 53 months, the 3-year OS, PFS, and LF rates were 48.1 %, 33.0 %, and 19.2 %, respectively. Grade 3 or higher adverse events were observed in 5 patients (5.2 %), with no Grade 5 events reported. In multivariate analysis, concomitant interstitial lung disease and low vital capacity were identified as significant prognostic factors for both OS and PFS. No statistically significant associations with OS or PFS were detected for tumor size > 5 cm, treatment modality, or chemotherapy.
Particle therapy showed encouraging survival outcomes and a low reported incidence of severe toxicity in patients with cT3N0M0 NSCLC, potentially offering a definitive treatment option for those who are medically inoperable or decline surgery.

PMID:
43020138
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement